PubMed Health⌕ Search

Biomedical subjects

I A Abugova

Publications and source records attributed to I A Abugova.

9 recordsLinked to original sources
PubMed1994

Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion.

Type 1 diabetes mellitus is associated with decreased insulin-like growth factor-1 (IGF-1) levels, enhanced values of growth hormone (GH) and IGF-binding protein 1 (IGFBP-1). Since the liver is the major source of IGF and IGFBP production, we have therefore examined whether levels of IGFs (IGF-1 and IGF-11) and IGFBPs (IGFBP-1 and IGFBP-3) differ when insulin is infused into the portal or peripheral vascular system. IGF, IGFBP, and GH levels were determined within 1-3 weeks of diagnosis in 36 patients (ranging in age from 18 to 22 years) with Type 1 diabetes mellitus. IGF-1 levels were low before insulin therapy administration (0.49 +/- 0.05 vs. 1.11 +/- 0.04 U/ml in controls, P < 0.01). With insulin treatment, IGF-1 levels rose to the normal range and IGF-1 normalisation depended on diabetes control and the route of insulin infusion. Diabetic patients with conventional insulin therapy (CIT; n = 12) had low IGF-1 (0.57 +/- 0.07 U/ml) compared with patients with continuous subcutaneous insulin infusion (CSII; n = 12; 0.75 +/- 0.08 U/ml; P < 0.05) and intraportal insulin infusion (IPII; n = 12; 1.07 +/- 10.05 U/ml; P < 0.05). Significant correlations were found between IGF-1 and parameters of glycemic control: HbA1c (r = -0.64; P < 0.01) and glycemia (r = -0.56; P < 0.05). The pattern of changes in IGF-11 levels was not significantly different from that of controls and was not altered by insulin therapy (0.98 +/- 0.08 and 1.01 +/- 0.04 U/ml in controls). Measured fasting 08:00 h IGFBP-1 levels were elevated 3-fold and IGFGP-3 levels were 2-fold lower in diabetic patients than in controls. Elevated IGFBP-1 levels were significantly correlated with metabolic control (glycemia, r = 0.64, P < 0.01; HbA1c, r = 0.71, P < 0.01). The mean elevated GH level before insulin administration (13.4 +/- 0.9 mg/l) was decreased by intensified insulin therapy (CSII, 8.8 +/- 0.6, P < 0.05; IPII, 5.6 +/- 0.9 mg/l, P < 0.001). There was a negative correlation between GH and IGF-1 (r = -0.72, P < 0.01). These results show the role of glycemic control and the route of insulin administration in the normalisation of IGF-1, IGFBP-1 and GH up to non-diabetic controls in patients with recent-onset Type 1 diabetes mellitus.

Adult↗
PubMed1991

[Insulin-dependent complement activity in the serum of patients with diabetes mellitus].

Complement system was comparatively evaluated in 68 patients with diabetes mellitus and 104 healthy subjects. Hemolytic activity was examined for components C1, C2, C3, C4 and C5, and overall activity of the classic pathways was defined. The complement status appeared different for men and women. Females demonstrated hypofunction of the majority of the complement components, subcompensation in the absence of angiopathies, in decompensation complicated by angiopathies the activity was enhanced. In uneventful course of diabetes mellitus in males component C4 was activated remaining above normal though reduced in decompensation with angiopathies. High complement level in females could serve an aggravating factor, it depends on the dose of exogenic insulin.

Adolescent↗
PubMedDate not supplied

[Change of the complement level in patients with insulin-dependent diabetes mellitus in the course of intensified insulin therapy].

Intensified insulin therapy in patients with type I diabetes mellitus is accompanied by a decrease in a total daily dose of insulin and the activity of the first 5 components of the classical pathway and CH50. A decrease in function of the first 5 components of the complement against a background of intensified insulin therapy can serve as a positive prognostic criterion of stabilization of development of diabetic angiopathies.

Adolescent↗
PubMedDate not supplied

[Parameters of cellular and humoral immunity in patients with diabetes mellitus in the early stages of disease development; experience in treatment with the immunosuppressant azathioprine].

A total of 40 patients with type I diabetes mellitus, in whom the disease was diagnosed 1 to 12 months previously, were examined. An imbalance between the T and B cellular components of the immunity was found in the patients with the early stages of the disease, as was an elevated titer of the complement C1 component as against the reference group. The degree of the immunologic shifts was in direct correlation with the HLA A9 antigen expression, this relationship being the most marked in cases with the HLA DR3 and DR4. The incidence of these antigens expression was significantly higher in the patients with marked immunity shifts, than in those with negligible immunity changes. Therapy with an immunosuppressant azathioprine was associated with a noticeable reduction of the initially elevated cellular immunity parameters (total T and B lymphocyte counts, T helpers-inductors, DR carriers) and a trend towards a reduction of all the components and total activity of the classical route of the complement activation predominantly at the expense of the C1 and C5 components. The efficacy of this drug in therapy of new cases of insulin-dependent diabetes mellitus was confirmed, and the indisputable relationship between the efficacy of immunity suppression, that helped achieve a clinical remission, and the disease duration, was demonstrated. Monitoring of the cellular and humoral immunity parameters, of the activity of the classical route of the complement activation permitted an indirect judgement on the usefulness of immunity suppression for the correction of immunity disorders as factors contributing to the development of microvascular disturbances in insulin-dependent diabetes mellitus.

Adolescent↗
PubMedDate not supplied

[Immunologic characterization of patients with insulin-dependent diabetes mellitus with varying duration of disease].

The paper presents data on the cellular and humoral immunity in different periods of insulin-dependent diabetes mellitus (with the disease standing of 0.5 +/- 0.4 years, group A; 3 +/- 1.8 years, group B; and 15 +/- 4 years, group C). Group A patients presented with the immunity system activation: increased counts of T cells, B lymphocytes, T helpers and T inductors, increased share of active T cells (that is, DR positive ones), elevated content of IgM, IgG, IgA (214 +/- 51 mg%, 1200 +/- 124 mg%, 250 +/- 34 mg%, respectively) as against the reference group (156 +/- 74, 914 +/- 387, 189 +/- 49 mg%, respectively) (p < 0.01). In group B patients, who suffered a longer disease, the immunity parameters were within the normal range, and in group C patients, in whom the disease standing was the longest, these shifts were contrary-wise as against those in group A, that is, T and B cell counts were lowered, as were the counts of T-helpers-inductors, Ig levels, and the phagocytosis index was 65 +/- 5 vs. 85 +/- 10% in the controls (p < 0.05), the phagocytosis level being 4 +/- 2 vs. 10 +/- 2 in the controls (p < 0.05). The authors analyze the association of the HLA system characteristics with the immunity shifts. Patients with the HLA A9, B8, B15, B18, DR3, DR4 presented with significant shifts in the immunity status as against those with the HLA A1, A10, B5, B12, B16, B27, DR5, DR7.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMedDate not supplied

[Role of nicotinamide in the onset and course of streptozotocin-induced diabetes].

The authors have studied the preventive and therapeutic effects of high doses of nicotinamide on diabetes course in rats with streptozotocin-induced condition. Plasma glucose, glucosuria, C-peptide were assessed at the beginning of experiment and on day 40. Histologic studies were carried out over the course of experiment. On day 40 all rats administered nicotinamide showed almost normal glucose tolerance, and histologic examination showed just slight insulitis. In four of the six rats administered nicotinamide starting from the day when marked glucosuria first manifested glucosuria completely disappeared and their glucose tolerance improved over the course of therapy, though urinary sugar levels normalized in only one of the six rats administered nicotinamide for two weeks after the onset of marked glucosuria. These data evidence a preventive and therapeutic effect of nicotinamide on streptozotocin-induced diabetes in rats and suggest a reversible nature of beta-cell damage as early as at the initial stages of the disease.

Animals↗
PubMedDate not supplied

[Effect of azathioprine on immunologic parameters in patients with newly diagnosed insulin-dependent diabetes mellitus].

Azathioprine immunosuppressive therapy prolongs remissions and stimulates residual beta-cell function, suppresses insulin antibody production, reduces the activity of the complement and CH50 components, reduces initially increased cellular immunity parameters (total T and B cell counts, T helper to T inductor ratio, and the count of DR carrier cells) in patients with newly detected insulin-dependent diabetes mellitus; this makes this drug effective at the first stages of the disease. When selecting patients for immunosuppressive therapy the following immunity parameters should be examined: complement status, total counts of T and B lymphocytes, T-helper-inductor/T-suppressor-cytotoxic immunoregulation index, DR carrier cell counts. Reduced levels thereof are a contraindication against immunosuppressant therapy. Male patients with insulin-dependent diabetes mellitus debut at the age of over 25 are particularly susceptible to immunosuppressive therapy with azathioprine.

Adolescent↗